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The World Health Organization reported in
2000 concerning the “growing threat of
antimicrobial resistance.” Bacteriophages
are highly specific viruses that only infect a
small range of bacteria. Using
bacteriophages to treat bacterial infections
is called phage therapy. Research in
phage therapy began in the early 20th
century until the introduction of antibiotics.
While the US and other Western nations
moved away from phage therapy, the
Soviet Union and its satellite nations
continued to research phages. As phage
therapy was a standard of care in the
countries it was used in, the studies done
were not double-blind, placebo controlled
and not applicable to the standards of the
Food and Drug Administration (FDA) and
European Medicines Agency (EMA).
Viruses replicate by inserting their
genome into bacteria to replicate and express
their DNA (Figure 1). A phage can be either
lysogenic or lytic (Figure 2). A lysogenic
phage will initiate lysis, cell death,
immediately after all the phage parts are
made and assembled. A lysogenic phage
genome will remain latent in the bacteria’s
genome for several generation until lysis is
induced.
Phage therapy involves give a patient a
does of phage which would then replicate at
the site of infection (Figure 3)until there was
no longer a sufficient host to infect. Phage
therapy can be applied after identifying the
bacteria and matching the bacteria to a
phage. The other way involved giving the
patient a cocktail of phage with a wide host
ranges.
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Many studies of phage therapy are in
different stages of production. There are
available phage cocktail available from
Microgen in Russia and the Eliavia Institute
in Georgia where phage therapy is used as
an over the counter drug. The Nestle
Research company is currently studying
these phage cocktails under double-blind,
placebo controlled conditions (Brüssow,
2012). One study that is treating
pseudomonas infections in the ear have
research stage III clinical trials which are
the last phase before distribution to the
public (Wright, Hawkins, Ӓnggård, &
Harper, 2009).
One of the largest hurdle for phage
therapy is the financial hurdle with new
drugs costing $10-$50 million to create
(Brüssow, 2012). Companies are unwilling
to pursue phages as they cannot patent
the phage itself. They can however patent
the technology and techniques used to
isolate and propagate their phage.
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• Bacteriophage identification
• Potency and biological activity of
bacteriophages
• Control of sterility
• Manufacturing process considerations
• Lytic phages
(Parracho, Burrowes, Enright, McConville, &
Harper, 2012)
Bacteriophages Antibiotics Comments
Very specific Target all micro 
flora
High specificity can 
be 
disadvantageous
Replicate at the 
site of infection
Metabolized and 
eliminated from 
body
Exponential growth 
of phage may 
require fewer 
administrations
No serious side-
effects described
Multiple side 
effects including 
allergies and 
secondary 
infections
Minor side effects 
of phage therapy 
may have been 
caused by release 
of endotoxins
Phage resistant 
bacteria remain 
susceptible to other 
phages with similar 
host range
Resistant to 
antibiotics not 
limited to targeted 
bacteria
Antibiotics select 
for many resistant 
bacterial species
• Gene Transfer
• Changing Host range
• Antibiotic Resistance Transfer
• Identification o bacteria
“Concentrate on pathogens that represent
the greatest problems with respect to
antibiotic resistance like staphylococci,
enterococci, klebsiellae, and enterobacteria.
Some Klebsiella pneumoniae and E. coli
isolates are already resistant against all
known antibiotics and patients with these
pathogens are doomed. Targeting these
infections with phages might thus address a
medical emergency.” (Brüssow, 2012, p.
141).
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